Data from the phase 3 TULIP studies showed that treatment of systemic lupus erythematosus (SLE) patients with anifrolumab resulted in more British Isles Lupus Assessment Group (BILAG)-based Combined Lupus Assessment (BICLA) responses compared with placebo, starting at early timepoints and being sustained through week 52. Prof. Eric Morand (Monash University, Australia) who presented these studies, stated that rapid and durable BICLA response supports the clinical benefit of anifrolumab for patients with moderately to severely active SLE .
The human monoclonal antibody anifrolumab is a type I interferon (IFN) receptor antagonist, which has previously shown promising results in the phase 3 TULIP-2 and TULIP-1 trials in SLE [2,3]. Both TULIP-2 (anifrolumab n=180; placebo n=182) and TULIP-1 (anifrolumab n=180; placebo n=184) were randomised, double-blind, placebo-controlled trials which evaluated the efficacy and safety of anifrolumab (300 mg every 4 weeks)...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Subclinical myocardial involvement progresses in SSc patients Next Article
COVID-19 and inflammatory rheumatic disease: some key issues »
Table of Contents: EULAR 2020
Osteoporosis and Osteoarthritis
Systemic Sclerosis and Systemic Lupus Erythematosus
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.